Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | HER2amp | Luminal | (Z)-4-Hydroxytamoxifen | ESR1 | 0.0107 | uM | 7914.016 | 0.9450 | 0.9316 | 1.6240 | ||
| SK-BR-3 | HER2amp | Luminal | (Z)-4-Hydroxytamoxifen | ESR1 | 0.0533 | uM | 7914.016 | 0.9087 | 0.8855 | 1.6240 | ||
| SK-BR-3 | HER2amp | Luminal | (Z)-4-Hydroxytamoxifen | ESR1 | 0.267 | uM | 7914.016 | 0.9328 | 0.9161 | 1.6240 | ||
| SK-BR-3 | HER2amp | Luminal | (Z)-4-Hydroxytamoxifen | ESR1 | 1.33 | uM | 7914.016 | 0.8868 | 0.8574 | 1.6240 | ||
| SK-BR-3 | HER2amp | Luminal | (Z)-4-Hydroxytamoxifen | ESR1 | 6.67 | uM | 7914.016 | 0.7807 | 0.7173 | 1.6240 | ||
| SK-BR-3 | HER2amp | Luminal | (Z)-4-Hydroxytamoxifen | ESR1 | 33.3 | uM | 7914.016 | 0.8159 | 0.7645 | 1.6240 | ||
| SK-BR-3 | HER2amp | Luminal | (Z)-4-Hydroxytamoxifen | ESR1 | 167 | uM | 7914.016 | 0.7024 | 0.6091 | 1.6240 | ||
| SK-BR-3 | HER2amp | Luminal | (Z)-4-Hydroxytamoxifen | ESR1 | 0.000427 | uM | 9759.019 | 1.0324 | 1.0471 | 1.3677 | ||
| SK-BR-3 | HER2amp | Luminal | (Z)-4-Hydroxytamoxifen | ESR1 | 0.00213 | uM | 9759.019 | 0.9515 | 0.9286 | 1.3677 | ||
| SK-BR-3 | HER2amp | Luminal | (Z)-4-Hydroxytamoxifen | ESR1 | 0.0107 | uM | 9759.019 | 0.9794 | 0.9698 | 1.3677 | ||
| SK-BR-3 | HER2amp | Luminal | (Z)-4-Hydroxytamoxifen | ESR1 | 0.0533 | uM | 9759.019 | 0.9692 | 0.9548 | 1.3677 | ||
| SK-BR-3 | HER2amp | Luminal | (Z)-4-Hydroxytamoxifen | ESR1 | 0.267 | uM | 9759.019 | 1.0092 | 1.0135 | 1.3677 | ||
| SK-BR-3 | HER2amp | Luminal | (Z)-4-Hydroxytamoxifen | ESR1 | 1.33 | uM | 9759.019 | 0.9778 | 0.9674 | 1.3677 | ||
| SK-BR-3 | HER2amp | Luminal | (Z)-4-Hydroxytamoxifen | ESR1 | 6.67 | uM | 9759.019 | 0.8792 | 0.8203 | 1.3677 | ||
| SK-BR-3 | HER2amp | Luminal | (Z)-4-Hydroxytamoxifen | ESR1 | 33.3 | uM | 9759.019 | 0.7812 | 0.6696 | 1.3677 | ||
| SK-BR-3 | HER2amp | Luminal | (Z)-4-Hydroxytamoxifen | ESR1 | 167 | uM | 9759.019 | 0.1860 | -0.4154 | 1.3677 | ||
| SUM1315MO2 | TNBC | Basal B | (Z)-4-Hydroxytamoxifen | ESR1 | 0.000427 | uM | 7529.016 | 0.9799 | 0.9318 | 0.5847 | ||
| SUM1315MO2 | TNBC | Basal B | (Z)-4-Hydroxytamoxifen | ESR1 | 0.00213 | uM | 7529.016 | 0.9709 | 0.9014 | 0.5847 | ||
| SUM1315MO2 | TNBC | Basal B | (Z)-4-Hydroxytamoxifen | ESR1 | 0.0107 | uM | 7529.016 | 0.9928 | 0.9755 | 0.5847 | ||
| SUM1315MO2 | TNBC | Basal B | (Z)-4-Hydroxytamoxifen | ESR1 | 0.0533 | uM | 7529.016 | 1.0162 | 1.0559 | 0.5847 | ||
| SUM1315MO2 | TNBC | Basal B | (Z)-4-Hydroxytamoxifen | ESR1 | 0.267 | uM | 7529.016 | 0.9941 | 0.9798 | 0.5847 | ||
| SUM1315MO2 | TNBC | Basal B | (Z)-4-Hydroxytamoxifen | ESR1 | 1.33 | uM | 7529.016 | 0.9614 | 0.8697 | 0.5847 | ||
| SUM1315MO2 | TNBC | Basal B | (Z)-4-Hydroxytamoxifen | ESR1 | 6.67 | uM | 7529.016 | 0.8886 | 0.6343 | 0.5847 | ||
| SUM1315MO2 | TNBC | Basal B | (Z)-4-Hydroxytamoxifen | ESR1 | 33.3 | uM | 7529.016 | 0.9784 | 0.9266 | 0.5847 | ||
| SUM1315MO2 | TNBC | Basal B | (Z)-4-Hydroxytamoxifen | ESR1 | 167 | uM | 7529.016 | 0.9448 | 0.8150 | 0.5847 |